Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis
- 12 August 2008
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 12 (9), 1085-1096
- https://doi.org/10.1517/14728222.12.9.1085
Abstract
(2008). Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis. Expert Opinion on Therapeutic Targets: Vol. 12, No. 9, pp. 1085-1096. doi: 10.1517/14728222.12.9.1085Keywords
This publication has 108 references indexed in Scilit:
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesThe Journal of Experimental Medicine, 2007
- Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2007
- Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- TH-17 cells in the circle of immunity and autoimmunityNature Immunology, 2007
- Anti–TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-βThe Journal of Experimental Medicine, 2007
- Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trialAnnals Of The Rheumatic Diseases, 2006
- Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammationJCI Insight, 2006
- SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 productionNature Cell Biology, 2006